Metabolic dysfunction associated steatohepatitis

Overview

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive inflammatory liver disease that represents the advanced, aggressive form of metabolic dysfunction-associated steatotic liver disease (MASLD). It is histologically defined by hepatic steatosis (fat accumulation) occurring together with lobular inflammation, hepatocyte ballooning, and variable degrees of fibrosis. MASH marks a pivotal transition in the natural history of fatty liver disease: whereas simple steatosis is largely reversible, the sustained inflammatory and fibrogenic activity of MASH substantially raises the risk of progression to cirrhosis, hepatocellular carcinoma, and liver-related death. The condition was formerly termed non-alcoholic steatohepatitis (NASH); the renaming to MASH is part of a broader reclassification of steatotic liver disease that emphasizes underlying metabolic dysfunction and removes the stigmatizing "non-alcoholic" and "fatty" terminology, while distinguishing it from alcohol-related and combined (met-ALD) forms of liver injury.

MASH is tightly linked to the metabolic syndrome, and its development and progression are driven by obesity, type 2 diabetes, and insulin resistance, with lipotoxicity, oxidative stress, immune dysregulation, and activation of hepatic stellate cells contributing to inflammation and scarring. Its clinical burden extends beyond the liver: MASH is associated with substantial healthcare costs and with extra-hepatic complications, including cardiovascular disease and heart failure, and it commonly co-occurs with impaired kidney function as reflected in reduced glomerular filtration rate (eGFR). Because liver biopsy remains the diagnostic reference standard but is invasive, much current effort focuses on non-invasive risk stratification—using routine laboratory markers, imaging-derived measures such as liver MRI corrected T1 and proton density fat fraction, CT-based composite biomarkers, and machine-learning models—to identify patients with clinically significant fibrosis. Patients with stage F2–F3 (fibrotic) MASH constitute the principal target population for the emerging pharmacotherapies now entering clinical use.

Recent Publications Summary

Recent publications on metabolic dysfunction-associated steatohepatitis (MASH) have focused heavily on noninvasive risk stratification, treatment response, and progression to advanced liver disease. A prospective biopsy-based study in 413 patients with suspected or diagnosed MASLD proposed a simplified definition of at-risk MASH as MASH with fibrosis stage ≥2, rather than requiring both a higher NAS threshold and activity components, and found that this broader definition captured more patients needing clinical attention. In the same study, magnetic resonance elastography-derived liver stiffness showed the best diagnostic performance for identifying at-risk MASH and cirrhosis, outperforming FIB-4 and individual laboratory markers 42579768Aug. Complementing this, another imaging-focused study reported that a clinical records-based neural network combining patient history, routine laboratory tests, and ultrasound features improved fibrosis prediction versus FIB-4 and reduced liver biopsy failure rates for at-risk MASH prediction in external validation 42477328Jul. Additional work has also explored liver MRI-derived cT1 thresholds and proton density fat fraction as potential tools for refining mortality risk prediction in people at risk for MASH 42309239Jun.

Therapeutic studies continue to center on resmetirom and other candidate interventions. A post hoc analysis of the phase 3 MAESTRO-NASH trial examined patients with F2-F3 fibrosis, the label-consistent population for resmetirom, and reported higher rates of MASH resolution at week 52 with both 80 mg and 100 mg resmetirom compared with placebo 42527732Jul. Preclinical studies also identified several experimental approaches with anti-MASH activity, including Micranthin B, which was shown in diet-induced mice and hepatocytes to alleviate MASH progression by targeting G3BP1, suppressing stress granule formation, and reducing endoplasmic reticulum stress. Another multi-omics study evaluated Banxia Baizhu Tianma Decoction in an MCD diet-induced mouse model of MASH to characterize its therapeutic effects and mechanisms 41831735Mar.

Natural history and health-system burden have also been emphasized. A German real-world claims analysis identified substantial comorbidity and progression burden among 4,710 patients with MASH, with documented end-stage liver disease in a large fraction over follow-up and measurable healthcare costs associated with the disease 42483986Jul. In parallel, a meta-analysis of placebo arms from randomized trials was designed to estimate the incidence of cirrhosis among patients with fibrotic MASH, highlighting concern about short-term progression in the F2-F3 population targeted by emerging therapies 42315723Jun. Related epidemiologic work examined whether breastfeeding in infancy confers long-term protection against MASH and adverse liver outcomes in adulthood 42116208May.

Several publications framed MASH within the broader reclassification to steatotic liver disease and MASLD, including guideline and regional implementation discussions. Two 2026 evidence-based MASLD guidelines emphasized advanced fibrosis as the key determinant of liver-related morbidity and mortality and recommended FIB-4 as a first-line risk stratification tool with secondary assessment for higher-risk patients 42118685May42120590May. An Asia-Pacific perspective paper discussed the transition from NAFLD to SLD/MASLD/MASH terminology and the challenge of aligning new criteria with existing MAFLD-oriented practice 42315088Jun. Other work noted mitiperstat as a myeloperoxidase inhibitor under investigation for MASH among other diseases 42101107May, and a CT-based study aimed to develop composite biomarkers to identify MASH and steatosis grade in people with obesity prior to bariatric surgery 42135651May.

What Changes, What Holds

1. Noninvasive tools are moving toward a broader, more practical definition of at-risk disease
METHOD A biopsy-based threshold proposal and the better performance of liver stiffness and clinical-records models mainly change how MASH is identified and risk-stratified, not what MASH is. The most important implication is that “at-risk MASH” may be captured more effectively with stage-based fibrosis cutoffs and multiparametric noninvasive testing than with older activity-heavy definitions, which could widen eligibility for care and trials without displacing biopsy as the reference standard yet 42579768Aug42477328Jul.

2. Resmetirom remains the clearest near-term therapy signal, while preclinical leads stay exploratory
REINFORCES Higher histologic resolution rates with resmetirom in the target F2-F3 population strengthen the baseline view that fibrotic MASH is the main treatment target and that this agent has clinically relevant activity in that group 42527732Jul. The experimental mouse and cell findings for Micranthin B and Banxia Baizhu Tianma Decoction add mechanistic interest, but they do not alter the settled account because they are preclinical and do not yet change clinical use or disease biology in a decisive way41831735Mar.

3. Fibrotic MASH still appears to carry substantial near-term progression and cost burden
REINFORCES Real-world claims data and placebo-arm incidence estimates sharpen, rather than revise, the baseline warning that fibrotic MASH is the clinically consequential stage with meaningful risk of cirrhosis, end-stage liver disease, and healthcare burden 42483986Jul42315723Jun. The breastfeeding analysis opens a separate life-course question, but it does not yet change understanding of established adult risk drivers or progression pathways 42116208May.

4. Risk stratification is becoming more standardized around advanced fibrosis, not redefined by the nomenclature change
METHOD The guideline and implementation papers mainly refine how MASLD/MASH should be worked up: advanced fibrosis remains the key determinant of prognosis, FIB-4 is being positioned as first-line triage, and imaging or CT composite biomarkers are being developed to complement that pathway 42118685May42120590May42135651May. The terminology transition from NAFLD to SLD/MASLD/MASH is an implementation issue rather than a biological reversal, and the mitiperstat mention is only an investigational extension.

Overview update candidates: advanced fibrosis as the key prognostic determinant; broader adoption of FIB-4-first risk stratification with secondary testing; MRI cT1/PDFF; CT composites; and neural-network models as emerging noninvasive risk tools; resmetirom efficacy in F2-F3 MASH.